|
Showcase
|
|
|
|
1/16/2012
|
|
|
|
|
|
Sycrest - new and effective treatment for bipolar disorder
|
 |
|
|
Sycrest (asenapine), a new and effective treatment, is now available in the UK as a fast-dissolving sublingual tablet for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults. Sycrest is the first tetracyclic antipsychotic, structurally unrelated to existing atypical antipsychotics.
“Lundbeck has a well established heritage in mental health and CNS conditions. Sycrest is an important addition to our portfolio and an extremely important treatment option for appropriate adult patients with bipolar I disorder.” said Stephen Turley, UK managing director at Lundbeck.
Bipolar disorder affects close to 30 million people worldwide and an estimated 623,000 people in the UK. A new piece of patient insight research from the UK, with 988 respondents, has shown that many bipolar patients have concerns about their current treatment, with 44% of patients not satisfied with its efficacy.
“Coping with bipolar I disorder presents a very different challenge for each individual,” said Alison Cairns from Bipolar Scotland. “An increased number of treatment options give patients and their health professionals the best chance of finding the right treatment for them and Bipolar Scotland, Bipolar UK and SANE welcomes the addition of another treatment for bipolar I patients in UK.” For more information, visit www.lundbeck.com
|
|
|
|
|
|
|
|
|
|
|
